We are live on ! Find out more
EW icon

Edwards Lifesciences

90.78 USD
-0.09
0.1%
At close Updated Aug 26, 4:00 PM EDT
Pre-market
After hours
90.00
-0.78
0.86%
1 day
-0.1%
5 days
-0.91%
1 month
9.32%
3 months
3.7%
6 months
5.68%
Year to date
6.39%
1 year
11.7%
5 years
-22.38%
10 years
136.28%
 

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Employees: 16,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 45.5%
Neutral 50%
Negative 4.5%
Negative
Zacks Investment Research
6 days ago
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
Positive
Zacks Investment Research
12 days ago
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Positive
Zacks Investment Research
13 days ago
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Neutral
Seeking Alpha
20 days ago
Aristotle Value Equity WM Q2 2026 Portfolio Performance
For the second quarter of 2026, Aristotle Capital's Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Corteva, the seed and crop protection company, was one of the largest detractors during the period. Motorola Solutions, the provider of mission-critical communications and security systems, was one of the largest detractors during the quarter.
Aristotle Value Equity WM Q2 2026 Portfolio Performance
Neutral
Zacks Investment Research
27 days ago
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Positive
Benzinga
1 month ago
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Positive
Zacks Investment Research
1 month ago
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
Neutral
Seeking Alpha
1 month ago
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
Edwards Lifesciences Q2 Earnings Call Highlights
Edwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.
Edwards Lifesciences Q2 Earnings Call Highlights
Positive
Zacks Investment Research
1 month ago
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Price charts implemented using Lightweight Charts™